[Results with MOPP combination chemotherapy in Hodgkin's disease (author's transl)].
50 patients with Hodgkin's disease were treated with MOPP chemotherapy. Therapeutic success depended on previous treatment, stage of disease and histological subtype. Complete remission was achieved in 56%, partial remission in 28% and no response in 16% of the patients. None of the non-responders survived for longer than 2 years. Patients demonstrating partial remissions showed a median survival time of 3 years, whereas 23 out of 28 patients with complete remissions are still alive after 2 to 7 years. The median remission duration in cases of complete remission has not yet been reached, but would, at present, be not less than 48 months, with no patient at risk. 7 out of 9 patients who relapsed are on alternative treatment (ABVD, TNI) and doing well, the 2 remaining patients died in the course of the disease.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D011344:Procarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use*
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone
Behandlungsergebnisse mit MOPP-Therapie bei Morbus Hodgkin.